Malignant glioma is the most common aggressive adult primary tumor of the central nervous system. Treatments of malignant gliomas include surgery, radiotherapy and adjuvant temozolomide (TMZ) chemotherapy. However, inherent- and acquired resistance to TMZ present major obstacles to successful treatment, and the prognosis of patients with malignant gliomas remains very poor.

MJ-66, a synthetic qunazoline compound, was identified in our study as a potent anti-proliferative agent especially on human glioma with IC50 of approximately 60 nM. In intracranial glioma xenograft model, MJ-66 (0.14 mg/kg in saline, i.p., q.d., 10 days) significantly inhibited tumor growth and increased the survival of the experimental mice, however, did not decrease the body weight of mice.

Currently, there is a profound unmet medical need for a new drug in the treatment of malignant brain tumor. The MJ-66 demonstrated superior efficacy to TMZ that are the only first-line-drug in clinical use. MJ-66 is suggested to be a promising anticancer candidate.

Note: This abstract was not presented at the meeting.

Citation Format: Mann-Jen Hour, Tai-Lin Chen, Po-Wu Gean, Hong-Zin Lee. Development of MJ-66 as a novel anticancer agent for the treatment of malignant gliomas [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 5103. doi:10.1158/1538-7445.AM2017-5103